Epinephrine Syringes Deemed Safe for Continued Sale
Published Date: 6/2/2025
Notice
Summary
The FDA says epinephrine prefilled syringes for IV use weren’t pulled from the market because of safety or effectiveness problems. This means drug makers can keep getting approval to sell similar versions, so patients and healthcare providers won’t face shortages. No changes in cost or timing are expected, just smooth sailing ahead for this important medicine.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Epinephrine IV Syringe Remains Approved
The FDA determined that EPINEPHRINE (epinephrine) solution, 1 mg/mL, prefilled syringe for intravenous use was not withdrawn from sale for reasons of safety or effectiveness. Because of that, the FDA will not start procedures to withdraw approvals of abbreviated new drug applications (ANDAs) that refer to this product, which helps keep patient access stable.
Generic Applicants Can Keep Seeking Approval
The FDA said it will continue to approve ANDAs that refer to EPINEPHRINE 1 mg/mL prefilled syringe for IV use as long as applicants meet legal and regulatory requirements. That means drug makers can keep applying for approval of generic versions that rely on this product.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-06478 — Determination of Regulatory Review Period for Purposes of Patent Extension; VYLOY
The FDA has officially set the review period for VYLOY, a human biological product, so its patent holder can apply for extra patent time. This affects the company behind VYLOY, giving them a chance to extend their patent protection and potentially boost profits. If anyone thinks the dates are wrong or wants to challenge the company’s review speed, they must act by June 2 or September 30, 2026.
2026-06481 — Determination of Regulatory Review Period for Purposes of Patent Extension; HYMPAVZI
The FDA has set the official review period for HYMPAVZI, a new human biological product, so its patent holder can apply for extra patent time. This affects the company behind HYMPAVZI and anyone interested in patent extensions. If you think the dates are wrong or want to challenge the company’s diligence, you have until June 2 or September 30, 2026, to speak up—potentially impacting patent length and market exclusivity.
2026-06480 — Determination of Regulatory Review Period for Purposes of Patent Extension; EMRELIS
The FDA has officially set the review period for EMRELIS, a medicine patent, so the patent owner can apply for extra protection time. If anyone thinks the dates are wrong, they have until June 2, 2026, to speak up. Also, people can challenge whether the patent owner was diligent during the review by September 30, 2026. This affects patent holders and could impact how long they keep exclusive rights to their product.
2026-06479 — Determination of Regulatory Review Period for Purposes of Patent Extension; ENFLONSIA
The FDA has set the official review period for ENFLONSIA, a human biological product, so its patent holder can apply for extra patent time. This affects the company behind ENFLONSIA and anyone interested in patent rules. If you think the dates are wrong or want to challenge the company’s review speed, you have until June 2 or September 30, 2026, to speak up—potentially impacting patent length and market exclusivity.
2026-06477 — Determination of Regulatory Review Period for Purposes of Patent Extension; ENCELTO
The FDA has officially set the review period for ENCELTO, a medicine patent, so the company can apply to extend its patent protection. This affects the drug maker by potentially giving them more time to exclusively sell ENCELTO, which can mean more money. If anyone thinks the dates are wrong or the company wasn’t diligent, they have until June 2 or September 30, 2026, to speak up.
2026-06483 — Determination of Regulatory Review Period for Purposes of Patent Extension; INJECTAFER
The FDA has officially set the review period for INJECTAFER, a drug patent up for extension. This means the company can apply to extend their patent protection, potentially keeping their exclusive rights longer and impacting competition and pricing. If anyone thinks the dates are wrong or the company wasn’t diligent, they can speak up by June 2 or September 30, 2026.
Previous / Next Documents
Previous: 2025-09900 — M13B Bioequivalence for Immediate-Release Solid Oral Dosage Forms: Additional Strengths Biowaiver; International Council for Harmonisation; Draft Guidance for Industry; Availability
The FDA just dropped a draft guide to help drug makers skip extra tests for different pill strengths if one strength already proved it works. This means faster approvals and less hassle for companies making immediate-release tablets and capsules. If you’re in the drug biz, keep an eye out—this could save time and money starting late 2024!
Next: 2025-09902 — Performance Review Board Membership
The Merit Systems Protection Board just named the new members of its Senior Executive Service Performance Review Board, replacing all past member lists. This update affects senior federal employees who get reviewed for their job performance. No changes to pay or timing are mentioned, but it keeps the review process fresh and official.
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in